Radiosensitization of Adenoid Cystic Carcinoma with MDM2 Inhibition

Adenoid cystic carcinoma (ACC) is a rare cancer arising from the major or minor salivary gland tissues of the head and neck. There are currently no approved systemic agents or known radiosensitizers for ACC. Unlike the more common head and neck squamous cell carcinomas that frequently harbor TP53 mu...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2017-10, Vol.23 (20), p.6044-6053
Hauptverfasser:	Prabakaran, Prashanth J, Javaid, Amal M, Swick, Adam D, Werner, Lauryn R, Nickel, Kwangok P, Sampene, Emmanuel, Hu, Rong, Ong, Irene M, Bruce, Justine Y, Hartig, Gregory K, Wieland, Aaron M, Canon, Jude, Harari, Paul M, Kimple, Randall J
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenoid Animals Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Apoptosis Cancer Carcinoma, Adenoid Cystic - metabolism Carcinoma, Adenoid Cystic - pathology Carcinoma, Adenoid Cystic - therapy Disease Models, Animal Experimental design Female Growth inhibition Head & neck cancer Head and neck Head and neck carcinoma Humans Immunohistochemistry Inhibition Malignancy MDM2 protein Mice Mutation p53 Protein Phosphorylation Proto-Oncogene Proteins c-mdm2 - antagonists & inhibitors Radiation Radiation therapy Radiation-Sensitizing Agents - pharmacology Radiation-Sensitizing Agents - therapeutic use Radiosensitization Radiosensitizers Radiotherapy Radiotherapy Dosage Salivary gland Signal Transduction - drug effects Squamous cell carcinoma Tissues Tumor Suppressor Protein p53 - genetics Tumor Suppressor Protein p53 - metabolism Xenograft Model Antitumor Assays Xenografts
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Adenoid cystic carcinoma (ACC) is a rare cancer arising from the major or minor salivary gland tissues of the head and neck. There are currently no approved systemic agents or known radiosensitizers for ACC. Unlike the more common head and neck squamous cell carcinomas that frequently harbor TP53 mutations, ACCs contain TP53 mutations at a rate of
ISSN:	1078-0432 1557-3265
DOI:	10.1158/1078-0432.CCR-17-0969